AlisonSchramMD

PubMed

• Convergent evolution of BRCA2 reversion mutations under therapeutic pressure by PARP inhibition and platinum chemotherapy.
  Walmsley, C., Jonsson, P., Cheng, M., McBride, S., Kaeser, C., Vargas, H., Laudone, V., Taylor, B., Kappagantula, R., Baez, P., Richards, A., Noronha, A., Perera, D., ...> ;NPJ Precision Oncology. 2024 Feb 14
• The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboringgene fusions.
  Kim, D., Schram, A., Hollebecque, A., Nishino, K., Macarulla, T., Rha, S., Duruisseaux, M., Liu, S., Al Hallak, M., Umemoto, K., Wesseler, C., Cleary, J., Springfeld, ...> ;Future Oncology. 2024 Feb 13
• 2 citations
  Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
  Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A Boezio, Artemisa Bulku, Lucian DiPietro, Cary Fridrich, Adam Frost, Fabrizio Giord...> ;Cancer Discovery. 2024 Feb 8
• 3 citations
  A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
  Elena Garralda, Alison M Schram, Philippe L Bedard, Gary K Schwartz, Eunice Yuen, Samuel C McNeely, Silvia Ribeiro, Jason Cunningham, Yi Wang, Arantxa Urunuela, Xiaoji...> ;The Oncologist. 2024 Jan 5
• 11 citations
  RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
  Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B Barry Touré, Songping Zhao, Roberto Valverde, Patrick J O'Hearn, Demetri T Moustakas, Heike Schönherr, Na...> ;Cancer Discovery. 2023 Sep 6
• 8 citations
  Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
  Yonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, Helen Won, Yixiao Gong, Anne Marie Noronha, Yelena Y Janjigian, Zsofia K Stadler, Jason C Chang, Soo-Ryum Yang...> ;Nature Communications. 2022 Nov 23
• 21 citations
  Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
  Timothy A Yap, Aditya Bardia, Michael Dvorkin, Matthew D Galsky, J Thaddeus Beck, David R Wise, Oleg Karyakin, Gábor Rubovszky, Nikolay Kislov, Kristoffer Rohrberg, An...> ;JAMA Oncology. 2023 Jan 1
• 18 citations
  Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Ag...
  Alison M Schram, Nicoletta Colombo, Edward Arrowsmith, Vivek Narayan, Kan Yonemori, Giovanni Scambia, Amelia Zelnak, Todd M Bauer, Ning Jin, Susanna V Ulahannan, Marco...> ;JAMA Oncology. 2023 Jan 1
• 7 citations
  Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.
  E Borazanci, A M Schram, E Garralda, I Brana, M Vieito Villar, A Spreafico, M Oliva, N J Lakhani, K Hoffman, R M Hallett, D Maetzel, F Hua, J Hilbert, P Giblin, J Anid...> ;ESMO Open. 2022 Aug 1
• 2 citations
  CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
  Lisa Werr, Dennis Plenker, Marcel A Dammert, Carina Lorenz, Johannes Brägelmann, Hannah L Tumbrink, Sebastian Klein, Anna Schmitt, Reinhard Büttner, Thorsten Persigehl...> ;Molecular Cancer Therapeutics. 2022 May 4
• 39 citations
  Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
  Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J Sisso, Marissa S Mattar, Allan J W Lui, Morana Vojnic, Sara H Shameem, Thrusha Chauhan,...> ;Cancer Discovery. 2022 May 2
• 8 citations
  AKT mutant allele-specific activation dictates pharmacologic sensitivities.
  Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N Gorelick, Matthew T Chang, Debyani Chakravarty, Elena I Gavrila, Mark T A Donoghue, JianJong Gao, Swati Patel, ...> ;Nature Communications. 2022 Apr 19
• 6 citations
  Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.
  M Herman Chui, Jason C. Chang, Yanming Zhang, Ahmet Zehir, Alison M. Schram, Jason A. Konner, Alexander Drilon, Arnaud Da Cruz Paula, Britta Weigelt, Rachel N. Grisham> ;JCO Precision Oncology. 2021 Sep 16
• 17 citations
  NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
  Christian Rolfo, Alexander Drilon, David S. Hong, Caroline E. McCoach, Afshin Dowlati, Jessica J. Lin, Alessandro Russo, Alison M. Schram, Stephen V. Liu, Jorge Nieva,...> ;British Journal of Cancer. 2021 Sep 3
• 9 citations
  Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
  Jasmine H. Francis, James J. Harding, Alison M. Schram, Julia Canestraro, Dianna Haggag-Lindgren, Murk Heinemann, Anuja Kriplani, Komal Jhaveri, Martin H. Voss, Dean F...> ;JAMA Ophthalmology. 2021 Oct 1
• 3 citations
  Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
  Jasmine H. Francis, Julia Canestraro, Dianna Haggag-Lindgren, James J. Harding, Eli L. Diamond, Alexander Drilon, Bob T. Li, Gopa Iyer, Alison M. Schram, David H. Abra...> ;Ophthalmology. Retina. 2021 Jun 5
• 26 citations
  Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
  Alexander Drilon, Michael Duruisseaux, Ji Youn Han, Masaoki Ito, Christina Falcon, Soo-Ryum Yang, Yonina R. Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Angel...> ;Journal of Clinical Oncology. 2021 Jun 2
• 34 citations
  Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
  Jason C. Chang, Michael Offin, Christina Falcon, David N Brown, Brian Houck-Loomis, Fanli Meng, Vasilisa A. Rudneva, Helen Won, Sharon Amir, Joseph Montecalvo, Patrice...> ;Clinical Cancer Research. 2021 May 4
• 9 citations
  Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
  Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Li Ann Wong, Alison M. Schram, Hele...> ;NPJ Breast Cancer. 2021 Apr 16
• 3 citations
  Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.
  Aakash Desai, Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal, Stephen V. Liu, Balazs Halmos, Roman Groisberg, Enrique Grande, To...> ;Nature Reviews. Clinical Oncology. 2021 Mar 23
• 91 citations
  COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials.
  Aakash Desai, Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal, Stephen V. Liu, Balazs Halmos, Roman Groisberg, Enrique Grande, To...> ;Nature Reviews. Clinical Oncology. 2021 May 1
• 26 citations
  TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
  Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristo...> ;Cancer Discovery. 2021 Jan 1
• 10 citations
  Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis.
  Peter Miller, Adam S. Sperling, Christopher J. Gibson, Kaushik Viswanathan, Cecilia A. Castellano, Marie McConkey, John J Ceremsak, Martin S. Taylor, Sebastian Birndt,...> ;Blood. 2020 Dec 24
• 4 citations
  Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
  Sebastian Mondaca, Dazhi Liu, Jessica Flynn, Sandy Badson, Stefan Hamaway, Mrinal M. Gounder, Danny N. Khalil, Alexander Drilon, Bob T. Li, Komal Jhaveri, Alison M. Sc...> ;Cancer. 2020 Nov 15
• 25 citations
  Discovery through clinical sequencing in oncology
  Mark T.A. Donoghue, Alison M. Schram, David M. Hyman, Barry S. Taylor> ;Nature Cancer. 2020 Aug 10
• Join now to see all

Journal Articles

• Article Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer  
  Sarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
• Genome Doubling Shapes the Evolution and Prognosis of Advanced Cancers  
  Alison M Schram, Jose Baselga, Mark E Robson, David B Solit, Zsofia K Stadler, Nature

Lectures

• Clinicopathologic characteristics of fusion-positive cancers: A single-institution study. 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019